Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe

Melbourne (Australia) and Liège (Belgium) – 19^th November 2020. Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from the Walloon regional government in Belgium.

Advanced Nuclear Medicine Ingredients S.A. (‘ANMI’), a wholly owned subsidiary of Telix Pharmaceuticals Limited announces today that it has received a €545,000 (~AU$893,000) payment from the Walloon regional government in Belgium. This payment represents part of a €1,320,000 innovation grant awarded to ANMI to support the ongoing preclinical R&D and early clinical development of the Company’s prostate cancer imaging product TLX591-CDx (⁶⁸Ga-PSMA-11).

Under the terms of the grant, in the event that the innovation grant funding results in developments or intellectual property that are subsequently used in a commercialised product, a fixed portion of the amount awarded (30%) must be repaid over a period of 10 years.

Ludovic Wouters, Telix Pharmaceuticals EU President and ANMI Co-Founder stated, “The Walloon region has become a favourable environment for life science innovation and this continuing support validates our decision to expand Telix’s footprint in Belgium with the recent acquisition of the radiopharmaceutical manufacturing facility in Seneffe.  We appreciate the region’s commitment to the biotechnology sector, a primary factor in Telix’s choice of Wallonia as our European headquarters.”

Read the full ASX release here.